组织条例 2025年5月27日 BeOne Medicines Ltd. 百济神州有限公司 一家瑞士公司，注册地址位于瑞士巴塞尔城市州巴塞尔 1 1. 范围和依据 (a) 本《组织条例》（"本条例"）由BeOne Medicines Ltd.（"公司"）董事会（"董 事会"）根据于1911年3月30日颁布并经不时修订的《瑞士债法典》（《瑞" 士债法典》"）第716b条以及公司的《公司章程》（《公司章程》 " "）第19条第2 款、第21条第1款至第3款和第22条第3款的规定制定。 (b) 公司执行机构的公司治理、内部组织、职责、权力和责任受以下条款规 范 ： (i) 《公司章程》； (ii) 本条例 ； (iii) 公司的《企业管治准则》（《企业管治准则》 " "）； (iv) 《董事会组成政策》；以及 (v) 常设委员会章程。 2. 公司的执行机构 (a) 公司的执行机构如下 ： (i) 董事会，由董事会成员组成（分别称为"董事"）； (ii) 董事会主席（"董事会主席"）； (iii) 首席独立董事（根据第3(c)条任命）； (iv) 董事会的常设委员会和其他委员会（"委员会"）； (v) 公司的首席执行 ...

A股代码：688235 A股简称：百济神州 公告编号：2025-025 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于公司注册地变更相关事项的进展公告 2、自存续注册生效日起，公司适用根据瑞士法律制定的公司章程 （以下简称"瑞士章程"），同时本公司的英文名称（记载于瑞士章 程）变更为 BeOne Medicines Ltd.，本公司的中文名称保持不变。 3、自存续注册生效日起，瑞士的 Ernst & Young AG 担任公司的瑞 士法定审计师，任期直至公司存续注册完成后的第一届年度股东大会 召开之日止。安永华明会计师事务所（特殊普通合伙）将继续担任公 司的 A 股审计机构。 一、存续注册及其相关事项的具体情况 1 经公司2025年第一次临时股东大会（股东特别大会）审议批准， 公司股东同意本公司在瑞士进行存续注册，并自存续注册生效日起适 用瑞士章程以及选聘Ernst & Young AG担任公司的瑞士法定审计师，具 体参见公司于2025年3月11日披露的《百济神州有限公司2025年第一次 临时股东大会（股东特别大会）会议资料》以及于2025年4月29日披露 的《百济神州有限 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年5月21 日，董事會根據2016期權及激勵計劃的條款向九名獨立非執行董事授出可認購合 共15,750股美國存託股份的購股權及合共7,605股美國存託股份的受限制股份單 位。 2016期權及激勵計劃項下的購股權 於2025年5月21日，董事會授權根據2016期權及激勵計劃的條款向九名獨立非執 行董事授出可認購合共15,750股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： 1 授出日期： 2025年5月21日 已授出購股權涉及的 相關股份數目： 204,750 購股權總數（美國存託股份）: 15,750 因已授出購股權獲行使而 可予認購的新美國存託 股份總數： 15,750 授出的代 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年5月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫 ...

Core Viewpoint - The recent capital movement involving BeiGene, a leading Chinese innovative drug company, has sparked significant discussion in the capital market, particularly following the reduction of shareholding by HHLR Fund, L.P., controlled by Hillhouse Capital, which decreased its stake from 6.03% to 4.89% after selling 16 million shares, realizing HKD 22.46 billion in cash [2][3][4]. Company Performance - As of December 31, 2024, BeiGene reported cumulative unabsorbed losses of CNY 62.667 billion, but showed signs of improvement in Q1 2025 with revenue of CNY 8.048 billion, a 50.2% increase from CNY 5.359 billion in the same period last year, and a significant reduction in net loss from CNY 1.908 billion to CNY 94.5 million [3][10][11]. - The company's core product, Zebrutinib, achieved global sales of CNY 18.859 billion, marking a 106.38% year-on-year increase, while another product, Tislelizumab, generated CNY 4.467 billion in sales, up 17.37% [10][11]. Shareholder Dynamics - Hillhouse Capital's gradual exit from BeiGene, which began in 2023, has seen its shareholding decrease by 5.72 percentage points in less than two years, raising questions about the motivations behind this strategic shift [4][8][9]. - The reduction in shareholding below 5% allows Hillhouse to avoid further disclosure obligations, indicating a potential shift in strategy and raising market speculation about future actions [8][9]. Industry Context - The biopharmaceutical industry is characterized by high R&D costs and long commercialization cycles, leading to ongoing operational losses for companies like BeiGene. The recent financial improvements, however, suggest a turning point in the company's operational performance [10][14]. - The competitive landscape in the biopharmaceutical sector is intensifying, with potential risks related to R&D bottlenecks and market pressures, which may influence investor confidence and capital flows [8][9][14].

Meeting Overview - The annual general meeting of BeiGene, Ltd. was held on May 21, 2025, at Mourant Governance Services (Cayman) Limited in the Cayman Islands [1] - A total of 271 ordinary shareholders attended the meeting, representing 995,428,431 voting rights, with 240 A-shareholders and 31 foreign shareholders [1] Voting Results - All proposals presented at the meeting were approved, with significant support from shareholders [2][3] - The voting results showed that 96.08% of ordinary shareholders voted in favor of the proposals, with A-shareholders showing a 95.55% approval rate [1][2] - The company confirmed that the voting procedures complied with relevant laws and regulations, including the Company Law and the rules of the Shanghai Stock Exchange [1][5] Board of Directors - The meeting included the appointment of Anthony C. Hooper and Ranjeev Krishana as third-class directors, with terms extending to the 2028 annual general meeting [4] - Shalini Sharp was appointed as a second-class director, also with a term until the 2028 annual general meeting [4] Auditor Appointment - The company appointed an independent auditor for the fiscal year 2025, which was approved during the meeting [4] Share Buyback - A proposal for the company to repurchase up to 10% of its shares (excluding A-shares and treasury shares) was approved [4]

Core Viewpoint - The legal opinion letter confirms the compliance of BeiGene, Ltd.'s 2025 Annual General Meeting (AGM) procedures with relevant Chinese laws and regulations, ensuring the legitimacy of the meeting and its resolutions [5][12][13]. Group 1: Meeting Procedures - The AGM was convened in accordance with the notice published on April 8, 2025, on the Shanghai Stock Exchange and other relevant platforms, meeting the 20-day notice requirement [6][7]. - The meeting utilized a combination of on-site voting, mail voting (for non-A shares), and online voting (for A shares), with the on-site meeting held on May 21, 2025, in the Cayman Islands [6][8]. Group 2: Voting Participation and Qualifications - A total of 271 shareholders participated in the voting, representing 995,428,431 shares, which is approximately 70.94% of the total shares eligible for voting [8][10]. - The qualifications of A-share shareholders were verified through the Shanghai Stock Exchange's voting system, while other shareholders' qualifications were confirmed by respective custodians [10][11]. Group 3: Voting Procedures and Results - The AGM addressed 12 ordinary resolutions, including the re-election of directors and the appointment of auditors, with specific resolutions requiring separate counting for A-share minority investors [11][12]. - All resolutions were passed as valid ordinary resolutions, confirming the effectiveness of the voting process [12][13].

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于百济神州有限公司（BeiGene, Ltd.） 2025 年年度股东大会的 法律意见书 致：百济神州有限公司（BeiGene, Ltd.） 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律执 业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席百济神州有限公 司（BeiGene, Ltd.）（以下简称"百济神州"或"公司"）2025 年年度股东大会（以下 简称"本次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会 议人员的资格、表决程序和表决结 ...

| A 股代码：688235 | 股简称：百济神州 A | 公告编号：2025-024 | | --- | --- | --- | | 港股代码：06160 | 港股简称：百济神州 | | | 美股代码：ONC | | | 百济神州有限公司 2025 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 21 日 （二） 股东大会召开的地点：Mourant Governance Services (Cayman) Limited 的 办公室，位于 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, 开曼群岛 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 271 | | --- | --- | | 普通股股东人数 | 271 | | 其中：A ...

Group 1 - The core index, the CESHKB, increased by 1.98% to 5775.66 points, with a trading volume of 6.408 billion [1] - Over the past month, the CESHKB has risen by 7.34%, by 17.05% over the last three months, and by 28.90% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, set at 2000.0 points [1] Group 2 - The top ten holdings of the CESHKB include: Innovent Biologics (10.8%), CanSino Biologics (10.42%), WuXi Biologics (10.27%), China National Pharmaceutical Group (9.64%), BeiGene (9.22%), Kelun-Biotech (5.32%), Zai Lab (5.26%), WuXi AppTec (5.16%), 3SBio (5.15%), and Genscript Biotech (3.23%) [1] - The CESHKB is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% representation [2] - The industry representation of the CESHKB is entirely in the healthcare sector, specifically pharmaceuticals and biotechnology, also at 100% [2]